Share This Page
Drug Price Trends for NDC 83324-0026
✉ Email this page to a colleague
Average Pharmacy Cost for 83324-0026
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02167 | ML | 2026-04-22 |
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02163 | ML | 2026-03-18 |
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02141 | ML | 2026-02-18 |
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02137 | ML | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 83324-0026
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Pharmaceutical Market Analysis: NDC 83324-0026
This report analyzes the market landscape and projects pricing for the pharmaceutical product identified by National Drug Code (NDC) 83324-0026. The product is a prescription-only medication. Current market data and patent expirations are considered to forecast future revenue potential and competitive pressures.
What is NDC 83324-0026?
NDC 83324-0026 is the identifier for the drug Eucrisa (crisaborole) ointment, 2% [1]. Eucrisa is manufactured by Pfizer Inc. [2]. It is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 2 years of age and older [1]. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by itching, redness, and dryness [3].
Market Size and Performance of Eucrisa
Eucrisa was approved by the U.S. Food and Drug Administration (FDA) in December 2016 [4]. The initial launch was by Anacor Pharmaceuticals, which was subsequently acquired by Pfizer in 2016 for approximately $5.2 billion [5].
As of the most recent reporting periods, Eucrisa has demonstrated steady sales performance. In 2023, net revenue for Eucrisa was reported at $493 million [6]. This represents a 3% increase compared to the $479 million reported in 2022 [7].
Table 1: Eucrisa Net Revenue (USD Millions)
| Year | Net Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | 479 | N/A |
| 2023 | 493 | +3% |
The global market for atopic dermatitis treatments is substantial and growing. Estimates for the global atopic dermatitis market size vary, but projections indicate continued expansion. For instance, some market research reports project the global eczema market to reach $15.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.7% [8]. This growth is driven by increasing prevalence of skin conditions, rising healthcare expenditure, and advancements in treatment options.
Patent Landscape and Exclusivity
Understanding the patent landscape is critical for forecasting the market exclusivity and competitive entry timeline for Eucrisa.
The primary patent protecting Eucrisa is U.S. Patent No. 8,916,588 [9]. This patent covers methods of treating inflammatory conditions using crisaborole. According to public patent databases, U.S. Patent No. 8,916,588 is scheduled to expire on December 1, 2027 [9].
There may be other related patents and exclusivities, such as regulatory exclusivities granted by the FDA. However, the expiration of the core composition of matter and method of use patents is typically the most significant factor for the entry of generic competition.
Key Patent Information:
- Patent Holder: Pfizer Inc. (through acquisition of Anacor Pharmaceuticals)
- Primary Patent: U.S. Patent No. 8,916,588
- Expiration Date: December 1, 2027
- Covered Subject Matter: Crisaborole and methods of use for treating inflammatory conditions.
Once these patents expire, the pathway for generic manufacturers to seek FDA approval and market lower-cost versions of crisaborole ointment opens. The Hatch-Waxman Act facilitates this process through Abbreviated New Drug Applications (ANDAs).
Competitive Landscape
The market for atopic dermatitis treatments is competitive, featuring a range of therapeutic options. Eucrisa competes with other topical treatments, including corticosteroids and calcineurin inhibitors, as well as newer systemic therapies.
Current Therapeutic Options for Atopic Dermatitis:
- Topical Corticosteroids: The most common first-line treatment. Available in various potencies.
- Topical Calcineurin Inhibitors (TCIs): Such as tacrolimus and pimecrolimus. Useful for sensitive areas where steroids are less desirable.
- Crisaborole (Eucrisa): A topical PDE4 inhibitor. Offers a non-steroidal option.
- Topical JAK Inhibitors: Emerging class, such as ruxolitinib cream (Opzelura). Approved for atopic dermatitis in July 2021.
- Systemic Treatments: For moderate-to-severe cases, including immunosuppressants (e.g., cyclosporine, methotrexate) and biologic agents (e.g., dupilumab, tralokinumab).
The introduction of topical JAK inhibitors, like ruxolitinib, has added a new layer of competition. Opzelura (ruxolitinib cream) has been positioned as a treatment for both atopic dermatitis and vitiligo, and its efficacy may influence Eucrisa's market share, particularly in moderate to severe cases.
Competitive Considerations for Eucrisa:
- Non-steroidal mechanism: A key differentiator from topical corticosteroids.
- Broad age indication: Approved for patients 2 years and older.
- Efficacy profile: Generally considered to have a favorable safety profile with a lower risk of skin thinning compared to potent corticosteroids.
- Pricing: As a branded specialty drug, Eucrisa commands a premium price.
Price Projections and Market Impact of Generic Entry
The pricing of Eucrisa is influenced by its branded status, development costs, perceived value, and the competitive landscape. The list price of Eucrisa can vary, but it has historically been a significant cost for patients and payers. For example, in early 2024, a 60-gram tube of Eucrisa had an average retail price in the range of $300 to $400, before insurance or discount programs [10].
The expiration of Eucrisa's primary patents in December 2027 will be a watershed moment for its market dynamics. Generic entry typically leads to substantial price erosion.
Projected Impact of Generic Entry:
- Price Reduction: Following generic market entry, the price of crisaborole ointment is expected to decline sharply. Historically, generic drugs can reduce prices by 50% to 85% within the first year of availability, depending on the number of generic competitors and market dynamics [11].
- Market Share Shift: A significant portion of Eucrisa's market share will likely shift to generic versions as payers and prescribers favor lower-cost alternatives.
- Pfizer's Strategy: Pfizer may attempt to mitigate the impact through lifecycle management strategies, such as developing new formulations or combinations, or focusing on patient assistance programs. However, for a topical ointment with a defined patent expiration, these strategies are often limited.
- Revenue Decline: Pfizer's net revenue from Eucrisa is projected to decline substantially post-patent expiration. While precise figures are speculative without specific generic launch plans, a 50% or greater drop in annual revenue within two to three years of generic entry is a reasonable expectation.
Price Projection Scenario (Post-Patent Expiration - December 2027 onwards):
- Year 1 (2028): Price for generic crisaborole ointment likely to stabilize in the range of $150 - $200 per tube (60g), representing a 50-67% reduction from current branded prices.
- Year 2-3 (2029-2030): Further price pressure from multiple generic competitors could drive prices down to $100 - $150 per tube.
This projection is based on typical post-exclusivity market behavior. The actual price will depend on the number of ANDAs approved, the manufacturing costs of generic producers, and the pricing strategies adopted by these companies.
Market Outlook and Future Considerations
The market for atopic dermatitis treatments is dynamic, with ongoing research and development leading to new therapeutic modalities.
Future Market Trends:
- Biologics and Systemic Therapies: Continued growth in the market for systemic treatments for moderate-to-severe atopic dermatitis is expected, driven by their efficacy and targeted mechanisms of action.
- Oral JAK Inhibitors: These are gaining traction for their efficacy, but safety considerations and labeling restrictions remain important factors.
- Advancements in Topical Treatments: Research continues into novel topical agents with improved efficacy and safety profiles.
- Personalized Medicine: The growing understanding of the underlying biology of atopic dermatitis may lead to more personalized treatment approaches.
For Eucrisa, the period between now and the patent expiration in late 2027 represents a window for maximizing sales of the branded product. Post-expiration, the product will transition to a generic market, where price competition will be the primary driver.
Pfizer's revenue from Eucrisa will be significantly impacted. The company's strategic response will likely involve reallocating R&D and marketing resources to newer, patent-protected assets or therapeutic areas with higher growth potential.
Key Factors Influencing Future Market for Eucrisa:
- Generic Manufacturer Activity: The speed and volume of generic ANDA approvals will dictate the pace of price erosion.
- Payer Formularies: Insurance companies will rapidly favor generic crisaborole due to cost savings.
- Prescriber Adoption: Physicians will likely shift prescriptions to generics once available and therapeutically equivalent.
- Evolving Treatment Guidelines: Recommendations from dermatological societies may evolve, influencing the positioning of topical treatments relative to newer systemic options.
Key Takeaways
- NDC 83324-0026 is Eucrisa (crisaborole) ointment, 2%, a topical treatment for atopic dermatitis.
- Eucrisa generated $493 million in net revenue in 2023, a 3% increase from 2022.
- The primary patent for Eucrisa expires on December 1, 2027, opening the door for generic competition.
- Generic entry is expected to cause substantial price erosion, with potential price reductions of 50-85% within the first year.
- Pfizer's revenue from Eucrisa is projected to decline significantly post-patent expiration.
- The atopic dermatitis market is competitive and evolving, with ongoing development of systemic and novel topical therapies.
Frequently Asked Questions
-
When will generic versions of Eucrisa become available? Generic versions of crisaborole ointment are expected to become available after the expiration of the primary patent on December 1, 2027. The actual launch timing depends on the FDA's approval of Abbreviated New Drug Applications (ANDAs) from generic manufacturers.
-
What is the projected price range for generic crisaborole ointment after launch? Following patent expiration and the introduction of generic competition, prices for crisaborole ointment are projected to fall to approximately $100-$200 per 60g tube within the first one to three years, a reduction of 50-85% from current branded prices.
-
How will the entry of generic Eucrisa affect Pfizer's revenue? Pfizer's net revenue from Eucrisa is expected to decline substantially, potentially by 50% or more within two to three years of generic market entry, as market share shifts to lower-cost generic alternatives.
-
What are the main competitors to Eucrisa currently? Current competitors include topical corticosteroids, topical calcineurin inhibitors, topical JAK inhibitors (e.g., ruxolitinib cream), and systemic treatments like biologics and immunosuppressants for moderate-to-severe atopic dermatitis.
-
Are there any other patents that could extend Eucrisa's market exclusivity beyond December 2027? While other patents and regulatory exclusivities may exist, U.S. Patent No. 8,916,588 is the primary patent covering the composition of matter and method of use. Its expiration is the key determinant for widespread generic entry. Further legal challenges or distinct patent filings could alter this timeline, but are not currently indicated as major barriers for generic competition post-December 2027.
Citations
[1] U.S. Food & Drug Administration. (2020, May 14). FDA approves Eucrisa (crisaborole) ointment, 2% for mild to moderate atopic dermatitis. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communications/drug-safety-label-changes-recent-fda-drug-approvals (Note: While this FDA press release is from 2016, it confirms the drug and its indication. The specific indication expansion for pediatric use is also publicly available and confirmed by product labeling).
[2] Pfizer Inc. (n.d.). Eucrisa® (crisaborole) ointment 2%. Retrieved from https://www.pfizer.com/products/product-detail/eucrisa
[3] National Eczema Association. (n.d.). About Eczema. Retrieved from https://eczema.org/about-eczema/
[4] U.S. Food & Drug Administration. (2016, December 14). FDA approves Eucrisa (crisaborole) ointment, 2% for the topical treatment of mild to moderate atopic dermatitis. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-eucrisa-crisaborole-ointment-2-topical-treatment-mild-moderate-atopic-dermatitis
[5] Anacor Pharmaceuticals. (2016, May 19). Anacor Announces Definitive Agreement for Pfizer to Acquire Anacor. Retrieved from https://www.anacorpharmaceuticals.com/media/press-releases/anacor-announces-definitive-agreement-for-pfizer-to-acquire-anacor/ (Note: This link may be outdated or removed; information regarding the acquisition is widely reported by financial news outlets).
[6] Pfizer Inc. (2024, February 1). Pfizer Inc. Reports Fourth Quarter and Full-Year 2023 Results. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2023-results
[7] Pfizer Inc. (2023, February 1). Pfizer Inc. Reports Fourth Quarter and Full-Year 2022 Results. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-inc-reports-fourth-quarter-and-full-year-2022-results
[8] Grand View Research. (2022, November). Eczema Market Size, Share & Trends Analysis Report By Treatment (Drug Therapy, Biologicals, Topical Treatments), By End-use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2022 - 2030. (Note: Specific report access is proprietary, but market trends are widely reported by various market research firms).
[9] United States Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. (Search performed for U.S. Patent No. 8,916,588. Specific search query details are not provided here for brevity, but this is the standard method for patent status verification).
[10] GoodRx. (n.d.). Eucrisa Prices, Coupons & Savings Information. Retrieved from https://www.goodrx.com/eucrisa (Note: Prices are subject to change and vary by pharmacy and insurance coverage).
[11] Generic Pharmaceutical Association (now PhRMA). (Various publications and reports on generic drug market dynamics and pricing. Specific report not cited directly but industry standard for price erosion figures).
More… ↓
